Experimental and clinical data demonstrate an antileukemia effect of acute graft-versus-host disease (aGVHD). In all, 58 pediatric patients with acute lymphoblastic leukemia (ALL) who had received an allogeneic bone marrow transplant (BMT) at our institution were retrospectively analyzed for a correlation between the development of aGVHD and leukemic relapse. Probability of relapse after 5 (3) years was 13% (7%) in patients developing grade II-IV aGVHD vs 30% in patients with grade 0 or I aGVHD. There was a trend for a difference of the point estimates at 3 years, but no overall significance because of an unusual late relapse. Moreover, we analyzed the impact of cyclosporin A (CsA) on aGVHD in a subgroup of 22 children who had received a matched sibling donor (MSD) BMT. An increased dose of CsA within the first 2 weeks after BMT led to decreased occurrence and severity of aGVHD (P ¼ 0.035). The cumulative CsA dose appeared to have more impact than the average CsA whole-blood levels within the first 2 weeks and than the CsA dose given from day 15 to 40. In this subgroup, no life-threatening aGVHD or death from aGVHD occurred. In all cases (6/22), leukemic relapse was the cause of death. We therefore suggest that there is a relation between dose of CsA and relapse rate in childhood ALL transplanted from a MSD. Graft-versus-host disease (GVHD) is the main complication of allogeneic BMT. Risk factors for acute GVHD (aGVHD) include degree of histocompatibility between donor and recipient, number of T cells in the graft, sex mismatch between donor and recipient, patient age, and the prophylactic regimen employed.
Acute lymphoblastic leukemia (ALL) is the most common indication for bone marrow transplantation (BMT) in children. Despite the more frequent use of allogeneic BMT, overall survival is still limited by leukemia relapse and transplant-related mortality (TRM).
Graft-versus-host disease (GVHD) is the main complication of allogeneic BMT. Risk factors for acute GVHD (aGVHD) include degree of histocompatibility between donor and recipient, number of T cells in the graft, sex mismatch between donor and recipient, patient age, and the prophylactic regimen employed. [1] [2] [3] On the one hand, GVHD is the major adverse complication, on the other, it is strongly correlated with a lower relapse rate induced through a graft-versus-leukemia (GVL) effect. [4] [5] [6] [7] [8] [9] Combined prophylaxis of cyclosporin A (CsA) and short-course methotrexate (MTX) is broadly accepted as an immunosuppressive standard since the combination led to a significant decrease in the incidence and severity of aGVHD and to a significant improvement in survival when compared to either CsA or MTX alone. 10, 11 Recent data from a prospective trial in a pediatric population suggest that the use of low CsA doses (1 mg/kg/day) is associated with a statistically significant reduction in leukemia relapse (compared with a group receiving 3 mg/kg/day), probably due to an increased GVL effect. 12 This retrospective study was undertaken to assess the influence of GVHD on relapse and survival after BMT in children with ALL. In addition, we wanted to evaluate the influence of CsA dose and whole-blood level on clinical outcome including aGVHD and relapse rate. Therefore, a subgroup analysis was performed in 22 children who received a matched sibling donor (MSD) BMT.
Patients and methods
The study design was a retrospective chart review of patients treated with allogeneic BMT at the Children's Hospital of the Hannover Medical School (MHH) from June 1986 until April 2001. A cohort of 58 children and adolescents (41 males and 17 females) with ALL was enrolled in the evaluation. The median follow-up of the surviving children was 6.4 years (range 1.6-12.5 years). A subgroup analysis was carried out in 22 children who had received their graft from an HLA-identical sibling. Patients were eligible for this subanalysis if the combination of CsA and MTX had been used, and if complete data were available including CsA doses and levels. This was the case in 22 of 37 MSD transplantations.
At the time of BMT, median patient age for the entire group was 10.8 years (range 0.9-19.3 years). Immunophenotype analysis at diagnosis and remission status at the time of BMT are shown in Table 1 . In all, 34 donors were male, 24 female. A total of 37 children received their graft from an MSD, whereas 21 were transplanted from other allogeneic donors (nine partially mismatched related donors; 10 matched unrelated donors; two partially mismatched unrelated donors). Conditioning regimens, additional immunosuppressive therapy with anti-T-cell antibodies, and GVHD prophylaxis varied to some degree and are shown in Table 2 . In 90% of the patients, bone marrow was the source of stem cells whereas 10% received peripheral blood stem cells (PBSC). No T-cell depletion was performed in MSD transplantation. Before non-MSD transplantation, T cells were removed in 10 cases. Recombinant human granulocyte colony-stimulating factor was used early (beginning before day þ 8) in 15 transplant recipients.
Acute GVHD was classified according to standard criteria. 13 Chronic GVHD (cGVHD) was assessed in patients surviving more than 100 days with sustained donor engraftment and defined as limited or extensive. 14 The basis for calculations of CsA dose were the doses documented daily in the patient's chart. Intravenous application was calculated as 100%, and oral dose as 50%. 15 To evaluate the role of whole-blood CsA levels, the median of the laboratory results (minimum level before next application: whole-blood monoclonal fluorescence polarization immunoassay) measured from day 1 to day 14 was calculated. 16 Results as presented were current as of July 31, 2004. The probability of event-free survival (EFS) after BMT was calculated using the Kaplan-Meier product limit estimator. Cumulative incidence curves of EFS are presented as estimates of the probability of certain events (relapse or death) and compared by the log-rank test. Fisher's exact test of crosstabs analysis was used to compare clinical outcome (GVHD, relapse, death) in terms of CsA dosage and level.
Results

Engraftment
All evaluable patients (surviving X30 days and complete data: n ¼ 48) engrafted, achieving 0.5 Â 10 9 /l neutrophils (median day 21, range 9-51 days). Secondary graft failure was observed in three cases (two died, one recovered), in the remaining cases myeloid engraftment was sustained.
Graft-versus-host disease
In 52 of 58 patients, data on occurrence and intensity of a GVHD was retrievable from the charts. Of the 52 patients, 37 developed aGVHD at a median post-transplant time of 13 days (range 6-80 days). In all, 22 patients had grade I (mild), nine patients had grade II (moderate), four patients grade III (severe), and two patients grade IV (lifethreatening) GVHD. The start of GVHD in the group of grade I/II (n ¼ 31) was at day 15 (range 8-80 days), and in the group of grade III/IV (n ¼ 6) at day 9 (range 6-15 days). Of the 51 patients surviving more than 100 days, 13 developed cGVHD, of whom 11 had previously developed aGVHD (one at grade I, five at grade II, four at grade III, one at grade IV). Chronic GVHD was graded as limited in 11 patients and as extensive in two. A total of 15 children did not develop aGVHD or cGVHD. Death in remission in three patients was a direct (n ¼ 1, aGVHD grade IV) or indirect (n ¼ 2; infection was cause of death in two patients with cGVHD grade II) consequence of GVHD. 
Relapse
Out of 58 children, 14 relapsed at a median of 4.9 months after BMT (range 2.3-43.8 months), and 10 within 1 year. The cumulative incidence of relapse was analyzed according to occurrence and severity of aGVHD (complete data available for 52 patients, including 13 patients who relapsed). The relapse rate was lower in patients developing grade II-IV aGVHD than in those without any, or with grade I aGVHD (at 5 years 13 vs 30%, P ¼ 0.41, at 3 years 7 vs 30%, P ¼ 0.07; Figure 1 ). The difference in relapse rates between patients with no aGVHD (5/15; 33%) and patients with grade I aGVHD (6/22; 27%) was not relevant.
Treatment-related mortality
Of 58 children, 12 died in remission, as a result of nonleukemic BMT-related causes, at a median of 2.8 months after transplantation (range 0.5-7.4 months). As mentioned, three children died as a result of GVHD. In three cases, lymphoproliferative disease was the cause of death. Two children died of infection (1pt: fusariosis; 1pt: transfusion transmitted hepatitis B), one of toxicity, and the remaining three were documented as TRM without further details. The cumulative mortality was 9% for children with grade I aGVHD, and 27% both for patients with no aGVHD and the group with more severe GVHD (P ¼ NS; data not shown).
Survival
The 5-year Kaplan-Meier estimate of EFS is 53% (Figure 2 ). The median time to death from any cause was 6.3 months (range 0.5-46.8 months). Kaplan-Meier estimated EFS was analyzed according to the occurrence of aGVHD. Patients without aGVHD showed a lower EFS (40 vs 61%, P ¼ 0.07) than those developing aGVHD ( Figure 3 ). There was no remarkable difference of EFS in patients with mild aGVHD compared to those with more severe aGVHD (data not shown). Table 3 shows the data of survival, TRM, relapse, and GVHD, in accordance to MSD and non-MSD transplants, respectively.
Correlation between CsA dosage and whole-blood level
In all, 44 of 58 patients received CsA and had complete data of dosage and whole-blood levels. Within this group, no correlation was observed between CsA dose given intravenously and CsA level measured within the first 2 weeks after BMT (Pearson's correlation 0.004).
Impact of CsA on GVHD in MSD transplantations
Within the subgroup of patients that had received grafts from MSD (n ¼ 22), six developed no aGVHD, 11 developed grade I, four grade II, and one grade III aGVHD. Grade IV was not observed within this subgroup. Three patients developed cGVHD. Six children died, all because of leukemic relapse (status at the time of transplantation: 3 pts., first remission; 2 pts., second remission; 1 pt.: partial remission). Regarding CsA dosage Table 4 . The early-low-dose group (early-LDG) was defined as the group of patients who received a cumulative dose of CsA of less than 32 mg/kg in the first 14 days (n ¼ 11, Table 4 ). The definition of late-low-dose group (late-LDG) was to have received a cumulative dose of CsA of less than 58 mg/kg between days 15 and 40 (n ¼ 11, median 43.8 mg/ kg, range 22-52 mg/kg, s.d. ¼ 9.4). Patients receiving more than 58 mg/kg in this period of time were classified in the late-high-dose group (late-HDG) (n ¼ 11, median 74.4 mg/ kg, range 64-118 mg/kg, s.d. ¼ 16.6). Patients could also be separated by CsA levels. The low-level group (LLG) was defined as having a median CsA level of less than 170 ng/ml in the first 14 days (n ¼ 11, median 150 ng/ml, range 80-165 ng/ml, s.d. ¼ 34.0). Patients having a higher median level than 170 ng/ml in this period of time were classified in the high-level group (HLG) (n ¼ 11, median 200 ng/ml, range 180-310 ng/ml, s.d. ¼ 36.7). It needs to be emphasized that the groups were defined retrospectively based on a mathematical cutoff (median of all values) to create two groups of the same size.
All patients in the early-HDG developed no, or mild, aGVHD. By contrast, in the early-LDG, six of the children had no or mild aGVHD, but the remaining five children had moderate or severe acute GVHD. This observation is statistically significant (P ¼ 0.035, see Table 5 ). There was no significant difference in developing aGVHD observed between the late-LDG and the late-HDG. Similarly, no difference was observed in this respect between the LLG and the HLG. All data are shown in Table 5 . Table 6 shows the cumulative dose of CsA according to severity of aGVHD. The rates of relapse were similar in early-HDG (n ¼ 3/11), early-LDG (n ¼ 3/11), late-HDG (n ¼ 4/11), late-LDG (n ¼ 2/11), HLG (n ¼ 2/11), and LLG (n ¼ 4/11).
Discussion
To our knowledge, this is the only retrospective study performed on a pediatric population accurately analyzing dosage and whole-blood levels of CsA as GVHD prophylaxis in children and adolescents with ALL undergoing BMT.
The results confirm once again that development of GVHD is associated with a lower incidence of leukemia relapse, probably due to a GVL effect. [5] [6] [7] One unusually late relapse, however, caused a high P-value for the overall test statistic (Gray's test). Owing to the limited number of patients, we did not analyze precursor-B-and T-ALL separately. Nevertheless, a large study demonstrated a similar GVL effect in T-and B-lineage ALL after MSD BMT. 9 Interestingly, relapse rates of patients with no aGVHD were similar to those with aGVHD grade I. This could mean that the GVL effect is not only related to occurrence but also to severity of aGVHD as well as to other factors, such as GVHD independent antileukemic donor natural killer cells. 17, 18 Moreover, our study indicates that the duration of EFS is longer in patients developing aGVHD than in those without GVHD. As mentioned, there was no difference of EFS in patients with mild aGVHD compared to those with more severe aGVHD. In comparison to patients with grade I aGVHD, the lower relapse rate of patients with grade II-IV aGVHD was compensated by an increased TRM rate.
Therefore, prophylaxis of GVHD is more than just the prevention of a side effect. It appears to be an important tool for modulating risk of relapse, and survival after BMT. The combination of CsA with a short-course of MTX is the most widely used form of aGVHD prophylaxis. Similar immunosuppressive protocols including CsA and MTX are used in different centers, but when analyzed in detail there is a considerable variability in the practical application, including dosage of CsA and target therapeutic whole blood concentrations. 11 The optimum way to use CsA is not known. Mainly, doses were chosen according to measured drug concentrations. Alternatively, fixed dose schedules were used. Reports of proper controlled studies on this subject are few. In the main, fixed CsA doses are reported rather than optimum target concentrations. In a cohort of adult patients, Bacigalupo et al 19 showed that 1 mg/kg/day during the first 3 weeks is associated with a higher incidence of aGVHD but lower treatment-related toxicity, lower relapse rate, and better survival than 5 mg/ kg/day. 19 Locatelli et al performed a similar prospective study in a pediatric population undergoing HLA-identical sibling BMT, and compared two different GVHD prophylaxis regimens. Here again, the use of low CsA doses (1 mg/ kg/day) was associated with a statistically significant reduction in leukemia relapse, compared to patients receiving 3 mg/kg/day. Reduction of CsA dosage led to a higher incidence of grade II to IV aGVHD. TRM within the first year was greater in the low-dose group, whereas deaths directly attributable to aGVHD were very few. Nevertheless, the long-term outcome -reduced relapse rate vs increased TRM -in a greater number of patients is uncertain. 12 To investigate the correlation between details of prophylaxis of aGVHD and clinical outcome, we undertook a subgroup analysis of a homogeneous group, consisting of 22 children. All patients received bone marrow from an HLA-identical sibling, and were treated with CsA and short-course methotrexate. Calculations were based on CsA dosages as given and whole-blood CsA levels, as determined daily. Remarkably, even in a single-center setting with a homogeneous population, there is a wide range concerning dosage, target therapeutic level, and duration of intravenous administration. Moreover, no correlation between dosage and level was observed (for this factor, all 44 children receiving CsA were included). This phenomenon, probably due to drug interaction and/or polymorphism in drug metabolism, can hardly be resolved in a retrospective trial. It also poses questions for the design of future studies.
Increased dosage of CsA within the first 2 weeks after BMT led to decreased occurrence and severity of aGVHD in the subgroup of MSD BMT patients. None of the patients receiving cumulatively more than 32 mg/kg during this period developed more than grade I aGVHD, whereas the probability of developing grade II or III aGVHD for patients treated with less CsA was almost 50%. The difference in CsA levels measured within the first 2 weeks, and the impact of CsA dosage given between days 15 and 40 was not significant. Six of the 22 children died, in all cases of leukemia relapse. Five of them had no or mild, and one (who was transplanted in PR) had severe aGVHD. In no case was death directly attributable to GVHD. Moreover, no patient developed grade IV aGVHD. Knowing the correlation between GVHD and leukemia relapse, it is reasonable to hypothesize that reducing GVHD prophylaxis (CsA dosage) -with an increase in GVHD, and hence an enhanced GVL effect -could reduce relapse risk. We could not demonstrate a direct relation between CsA dosage (or whole-blood CsA level) and relapse rate after BMT, probably due to the limited number of patients.
Another important point is the total dose of short-term MTX. Evaluation of the patients' charts revealed a high variation in cumulative doses actually given, ranging from 15 up to 45 mg/m 2 . We cannot exclude an influence of this factor on our results. Moreover, polymorphisms in MTX metabolism may interfere with observations of doses given and clinical results. 20 Our results indicate that aGVHD has a beneficial effect in reducing relapse rate in children with ALL. Moreover, we were able to appreciate the impact of CsA given within the first 2 weeks on development of aGVHD. Lifethreatening aGVHD or death from GVHD were not observed after MSD transplantation, in all cases leukemia relapse was the cause of death. In conclusion, based on our data, we hypothesize that there is a relationship between dosage of CsA and relapse rate in children with ALL undergoing MSD transplantation. These findings must be confirmed in a larger cohort of patients. In view of the heterogeneity of ALL and treatment protocols, future studies should probably concentrate on well-defined subsets of patients treated with a standard protocol in a prospective study design.
